Compare Kinross Gold Corporation (KGC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Pfizer Inc — how do they compare? Kinross Gold Corporation trades at $27.75 (market cap $32.29B), while Pfizer Inc trades at $26.39 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 4.7× Kinross Gold Corporation's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| KGC | PFE | |
|---|---|---|
Market Cap | $32.29B | $151.73B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $28.56 |
52-Week Low | $18.70 | $23.60 |
Enterprise Value | $30.37B | $203.22B |
Dividend Yield | 0.59% | 6.46% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KGC trades at $27.40, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $0.71 per share, beating estimates, and maintains robust fundamentals with a P/E of 10.36 and net income margin of 37.52%. Recent news includes an S&P credit upgrade to 'BBB' and progress on the Lobo-Marte project, signaling operational strength.
The outlook is positive, driven by earnings beats, rising free cash flow, and a consensus price target of $37.20 offering ~36% upside. Risks include cost pressures, gold price volatility, and execution of growth projects. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor Q3 2026 results for sustained momentum.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
